Slide 1: Noxopharm releases Nyrada corporate presentation
Date: 7 June 2018 Sydney, Australia For personal use only ASX Limited ASX: NOX 20 Bridge Street Noxopharm Limited SYDNEY NSW 2000 ABN 50 608 966 123 Registered Office and NOXOPHARM RELEASES NYRADA Operational Office: Suite 3, Level 4 CORPORATE PRESENTATION 828 Pacific Highway Gordon NSW 2072 Austral
Slide 2: Forward Looking Statements
Forward Looking Statements This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “shoul
Slide 3: US biotechnology company overview
❑ US biotechnology company (NYC-based) For personal use only ❑ Founded on Australian R&D ❑ 3 first-in-class drug candidates ❑ All for major unmet needs ❑ Primary focus on drugs for brain and peripheral nerve diseases and conditions 1
Slide 4: NYX-205 and NYX-330 focus areas
NYX-104 NYX-205 NYX-330 For personal use only ❖ Neuroprotection from ❖ Lowering high blood cholesterol Brain brain anddiseases nerve diseases High cholesterol/ heart disease 2
Slide 5: World-leading Scientific Advisory Board
We have assembled a world-leading Scientific Advisory Board For personal use only Prof. Gary Housley Junichi Nabekura Chair of Physiology, University of Professor of Physiology and Neuroscience New South Wales, Sydney and and a Vice-Director of the National Institute Founding Director of the of Phys
Slide 6: Neuro-protectant objectives
NYX-104 Neuro-protectant For personal use only Objectives To bring to market a drug that limits brain damage following stroke To help the 65% of stroke survivors who suffer disability requiring assisted living • by reducing the severity of the disability in the short-term • by providing for faster r
Slide 7: Neuro-protectant: Ischaemic stroke
NYX-104 Neuro-protectant For personal use only Ischaemic stroke 5
Slide 8: Neuro-protectant against expansion of brain death
NYX-104 Neuro-protectant against the expansion of brain death following brain damage For personal use only Original area of brain deprived of blood dies and does not recover. Zone around the central core of Stroke damage can be recovered if blood Concussion supply restored quickly. Traumatic brain i
Slide 9: Cost of stroke
NYX-104 Cost of stroke For personal use only 795,000 10% recover almost completely PEOPLE EACH YEAR YEAR in the U.S. in the US have have aa stroke stroke 25% recover with minor impairments 140,000 STROKE COSTS Indirect and direct PEOPLE EACH YEAR medical costs die from stroke in the US 40% STROKE AC
Slide 10: Neuroprotection
NYX-104 Neuroprotection • Loss of blood flow to brain regions in Stroke and Traumatic Brain Injury drives For personal use only dysregulation of neurochemicals, which in turn, leads to a massive loading of brain cells with calcium ions (Ca2+ _ hundreds-fold increases) – switching on cell death signa
Slide 11: Neuro-protection proof-of-concept
NYX-104 Neuro-protection proof-of-concept For personal use only Mouse model of human stroke. 2mm diameter area of brain death. 2 hours post Injury Mice given NYX-104 had smaller injury volumes compared to 9 control mice
Slide 12: Neuro-protection proof-of-concept
NYX-104 Neuro-protection proof-of-concept For personal use only NYX-104 treatment reduced expansion of brain injury by 56% 10
Slide 13: NYX-104 Development Program 2018-19
NYX-104 NYX-104 Development Program 2018-19 For personal use only • Provided proof-of-concept (mouse ischemia model) H1 2018 • Confirm target and signaling pathway (well advanced) Hit validation Proof of concept • Study in second animal model to observe symptomatic H2 2018 outcome (motor function, c
Slide 14: NYX-330 Cholesterol-lowering objectives
NYX-330 Cholesterol-lowering For personal use only Objectives To bring to market a drug that lowers LDL (‘bad’) cholesterol levels in blood by inhibiting the blood protein PCSK9 That will be used in combination with statin drugs: • To lower LDL cholesterol levels to target levels in the 2/3rds of pa
Slide 15: NYX-330 Cholesterol-lowering: LDL and HDL
NYX-330 Cholesterol-lowering For personal use only Two main forms of cholesterol: ➢ LDL = low density lipoprotein High levels of LDL are associated with increased risk of ➢ HDL = high density lipoprotein cardiovascular disease (heart attack and stroke) 33% (71 million) of US adults have ‘at risk’ LD
Slide 16: Statin drugs limitations
NYX-330 Cholesterol-lowering For personal use only Statin drugs are standard of care for patients with Statin drugs ‘at risk’ LDL levels. But……., Target LDL levels are achieved in: 60% patients, leaving 40% patients still exposed to risk Statins deliver limited cardiovascular benefit: For every 138
Slide 17: NYX-330 Cholesterol cycle
NYX-330 Cholesterol cycle For personal use only Cholesterol cycle. • Liver cell makes LDL-C. Blood protein, PCSK9, then discovered Statins block cholesterol production by • Releases into bloodstream. in 2005: liver cell. • LDL receptors on liver cell • Important component of cholesterol cycle BUT…….
Slide 18: Anti-PCSK9 antibodies and limited uptake
NYX-330 For personal use only Initial attempts to Repatha (Amgen) and Praluent (Sanofi/Regeneron) approved 2015. Health benefit of anti-PCSK9 develop a small molecule drug to block drugs validated. In combination with statins, boost LDL PCSK9-LDLR binding reduction by up to additional 60%. appear to
Slide 19: NYX-330 Novel PCSK9 inhibitor
NYX-330 Novel PCSK9 inhibitor For personal use only Australian chemists identify suitable First-in-class, small molecule inhibitor of binding site on PCSK9 for attachment of PCSK9. small molecule. Aim is to develop NYX-330 as: NYX-330 effectively blocks binding of • Once a day oral treatment PCSK9 t
Slide 20: NYX-330 PCSK9 inhibitor development
NYX-330 PCSK9 inhibitor • Novel family of PCSK9 inhibitor compounds discovered For personal use only H1 2018 • Proof-of-concept in mouse model (current) Validation • Patentability confirmed (International Examiner report) • Oral formulation studies H2 2018 • In vitro toxicity studies Formulation H1
Slide 21: Nyrada Business
Nyrada Business For personal use only Pre-clinical proof-of-concept/ translation into the clinic Large therapeutic areas of significant need Areas of considerable M&A activity First-in-class drugs with little or no competition 19
Slide 22: Value Drivers
Value Drivers For personal use only Large market Lack of Potential Experience High profile size competition inflection points Board and CEO No known current highly Three first-in-class Large community neuro-protectant. experienced in drugs capable of Anticipated problems. drug development achieving
Slide 23: Key Metrics
Key Metrics For personal use only Founding shareholding ▪ Noxopharm Ltd 67% ▪ Altnia Holdings Pty Ltd 33% Seed Round Raise o $4M (Feb 2018) o 38 New Shareholders o Convertible Notes o Each Note = 3 Shares and 2 Options o If all Notes converted and Options exercised, shareholding will be: • 60% Noxop
Slide 24: Disclaimer
Disclaimer For personal use only • This presentation has been prepared by Nyrada Inc (the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in the Company or as an inducement to make an offer or invitation to subscribe for or purchase any shares
Slide 25: Contact
Contact For personal use only Dr Graham Kelly Chief Executive Officer graham.kelly@nyrada.com 23